MX340738B - Terapia para deficiencia de a-galactosidasa a. - Google Patents

Terapia para deficiencia de a-galactosidasa a.

Info

Publication number
MX340738B
MX340738B MX2014010892A MX14010892A MX340738B MX 340738 B MX340738 B MX 340738B MX 2014010892 A MX2014010892 A MX 2014010892A MX 14010892 A MX14010892 A MX 14010892A MX 340738 B MX340738 B MX 340738B
Authority
MX
Mexico
Prior art keywords
galactosidase
deficiency
therapy
human
gal
Prior art date
Application number
MX2014010892A
Other languages
English (en)
Inventor
F Selden Richard
Borowski Marianne
P Gillespie Frances
M Kinoshita Carol
A Treco Douglas
D Williams Melanie
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX340738B publication Critical patent/MX340738B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a un método para producir a-Gal A humana purificada, que comprende (a) cultivar una célula humana genéticamente diseñada modificada para sobreexpresar y secretar a-Gal A humana en un medio; (b) recolectar el medio que comprende a-Gal A humana a partir de dichas células cultivadas; y (c) purificar a-Gal A humana a partir del medio mediante (i) pasar el medio sobre una resina de interacción hidrofóbica y eluir a-Gal A humana a partir de la resina, y (ii) pasar la a-Gal A humana eluida sobre columnas que contienen una resina de heparina inmovilizada, hidroxiapatita, una resina de intercambio de anión y una resina de exclusión por tamaño y eluir a-Gal A humana a partir de la columna final, en donde la a-Gal A humana purificada está libre de agentes de afinidad de lectina proteicos y agentes análogos de sustrato a-Gal A.
MX2014010892A 1996-09-13 1997-09-12 Terapia para deficiencia de a-galactosidasa a. MX340738B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13
PCT/US1997/016603 WO1998011206A2 (en) 1996-09-13 1997-09-12 THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
MX340738B true MX340738B (es) 2016-07-22

Family

ID=24862863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010892A MX340738B (es) 1996-09-13 1997-09-12 Terapia para deficiencia de a-galactosidasa a.

Country Status (21)

Country Link
EP (4) EP2327775A3 (es)
JP (7) JP4001925B2 (es)
KR (2) KR100547402B1 (es)
CN (1) CN1268741C (es)
AT (1) ATE286120T1 (es)
AU (1) AU4424497A (es)
CA (1) CA2265464C (es)
DE (1) DE69732129T2 (es)
DK (2) DK2374876T3 (es)
ES (3) ES2234032T3 (es)
HK (3) HK1022173A1 (es)
HU (2) HU227189B1 (es)
IL (2) IL128960A (es)
MX (1) MX340738B (es)
NO (4) NO328443B1 (es)
NZ (2) NZ506214A (es)
PL (1) PL190041B1 (es)
PT (1) PT1538202E (es)
RU (1) RU2179034C2 (es)
TW (1) TW585919B (es)
WO (1) WO1998011206A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP2147681A1 (en) * 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
CA2398995C (en) 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
ES2371913T3 (es) * 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
ES2547726T3 (es) 2005-11-18 2015-10-08 Tokyo Metropolitan Institute Of Medical Science Nueva enzima altamente funcional que tiene especificidad de sustrato modificada
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
PL1988823T3 (pl) 2006-02-09 2019-01-31 Genzyme Corporation Powolne dostarczanie dokomorowe
ES2549121T3 (es) * 2007-05-18 2015-10-23 Tokyo Metropolitan Institute Of Medical Science Composición farmacéutica para terapia de reemplazo enzimático
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
NZ713967A (en) 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US20130209436A1 (en) 2010-04-23 2013-08-15 Synageva Biopharma Corp. Lysosomal storage disease enzymes
US9453847B2 (en) 2010-07-19 2016-09-27 Shire Human Genetic Therapies, Inc. Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof
BR112013005673B1 (pt) 2010-09-09 2020-12-15 Alexion Pharmaceuticals, Inc Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
CA2854330A1 (en) * 2011-11-02 2013-05-10 Genentech, Inc. Overload and elute chromatography
KR20140138850A (ko) 2012-03-02 2014-12-04 샤이어 휴먼 지네틱 테라피즈 인크. Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법
CN104507503A (zh) * 2012-06-29 2015-04-08 康斯乔最高科学研究公司(Csic) 用于递送生物活性化合物的功能化脂质体
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
US20150275195A1 (en) 2012-10-24 2015-10-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
PT3237621T (pt) 2014-12-22 2023-07-20 Codexis Inc Variantes da alfa-galactosidase humana
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2019004446A1 (ja) 2017-06-30 2019-01-03 富士フイルム株式会社 ライソゾーム病処置剤
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
WO2024044697A2 (en) * 2022-08-24 2024-02-29 Walking Fish Therapeutics, Inc. Compositions and methods for treatment of fabry disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
JP2730923B2 (ja) * 1987-10-02 1998-03-25 ザイモジェネティクス，インコーポレイティド Ｂａｒ１分泌シグナル
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
CA2022983A1 (en) * 1989-08-11 1991-02-12 Mei-Huei Lai Expression of a functional insect specific toxin gene in mammalian cells
JPH06502071A (ja) * 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
JPH06503479A (ja) * 1991-10-16 1994-04-21 オラージェン，　インコーポレイテッド 動物体細胞の粒子−媒介トランスフォーメーション
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
CA2166488A1 (en) * 1993-07-02 1995-01-12 Marian N. Marra Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
NZ278809A (en) 1994-01-13 1998-03-25 Rogosin Inst Macroencapsulation of secretory cells in an agarose collagen gel material coated with agarose
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
MX9705943A (es) * 1995-02-15 1997-10-31 Amgen Inc Analogos de ligando mpl.

Also Published As

Publication number Publication date
ATE286120T1 (de) 2005-01-15
NO330687B1 (no) 2011-06-06
HU227189B1 (en) 2010-10-28
HK1162580A1 (zh) 2012-08-31
KR20000036078A (ko) 2000-06-26
PL190041B1 (pl) 2005-10-31
WO1998011206A2 (en) 1998-03-19
CN1268741C (zh) 2006-08-09
EP0935651A2 (en) 1999-08-18
WO1998011206A3 (en) 1998-08-13
JP2012019793A (ja) 2012-02-02
ES2581828T3 (es) 2016-09-07
NO20090583L (no) 1999-05-10
PL332188A1 (en) 1999-08-30
NO20110496L (no) 1999-05-10
PT1538202E (pt) 2014-04-22
JP2001504324A (ja) 2001-04-03
JP2009060918A (ja) 2009-03-26
TW585919B (en) 2004-05-01
EP1538202A3 (en) 2007-05-30
HK1074058A1 (en) 2005-10-28
JP4313381B2 (ja) 2009-08-12
EP2374876A3 (en) 2012-10-24
CA2265464C (en) 2007-06-26
NZ506214A (en) 2002-11-26
DE69732129D1 (de) 2005-02-03
ES2234032T3 (es) 2005-06-16
EP0935651B1 (en) 2004-12-29
EP2374876A2 (en) 2011-10-12
IL184637A (en) 2015-07-30
JP4001925B2 (ja) 2007-10-31
EP2327775A2 (en) 2011-06-01
HU1000445D0 (en) 2010-11-29
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
EP2374876B1 (en) 2016-04-13
JP2007000145A (ja) 2007-01-11
RU2179034C2 (ru) 2002-02-10
KR20050084473A (ko) 2005-08-26
AU4424497A (en) 1998-04-02
JP4313405B2 (ja) 2009-08-12
DK1538202T3 (en) 2014-03-24
DK2374876T3 (en) 2016-05-30
NO20141168L (no) 1999-05-10
NO991225L (no) 1999-05-10
JP5590788B2 (ja) 2014-09-17
CA2265464A1 (en) 1998-03-19
JP2009102321A (ja) 2009-05-14
NO340408B1 (no) 2017-04-18
HU230275B1 (hu) 2015-11-30
CN1230220A (zh) 1999-09-29
ES2458292T3 (es) 2014-04-30
HK1022173A1 (en) 2000-07-28
DE69732129T2 (de) 2005-12-08
IL128960A (en) 2007-10-31
EP2327775A3 (en) 2012-10-24
NO991225D0 (no) 1999-03-12
EP1538202B1 (en) 2014-01-22
HU9904666A (en) 2000-05-28
EP1538202A2 (en) 2005-06-08
IL184637A0 (en) 2009-09-22
NZ334721A (en) 2001-01-26
KR100547402B1 (ko) 2006-02-01
NO328443B1 (no) 2010-02-22
JP2015044830A (ja) 2015-03-12
JP2007289201A (ja) 2007-11-08

Similar Documents

Publication Publication Date Title
MX340738B (es) Terapia para deficiencia de a-galactosidasa a.
EP0923293A4 (en) DIARRHEA TREATMENT
AU6760987A (en) Method of treating alzheimer's disease
IN167680B (es)
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
PT2143420E (pt) Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry
HK1104836A1 (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof
NO883540D0 (no) Fremgangsmaate og anlegg for behandling av slam.
EP0461601A3 (en) Method and apparatus for maintaining the activity of an enzyme electrode
AU1505788A (en) A method and a composition for treating neurological diseases such as migraine, by influencing the nerve cells
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
DK505787A (da) Catecholderivater samt forebyggende og terapeutisk praeparat omfattende samme mod regressive sygdomme i centralnervesystemet
AU5323396A (en) Methods of treating inflammation and compositions therefor
DK1225906T3 (da) Mekanisk forlængede nerveceller og fremgangsmåde til at producere og anvende disse celler
UA26870C2 (uk) Спосіб підвищеhhя продукуваhhя протеїhу с, спосіб підвищеhhя рівhя його модифікації
IL131478A0 (en) Methods for treatment of scar tissue
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
CS275028B2 (en) Method of animal leather treatment and equipment for its realization
AU2816889A (en) Method for treatment of dyslipidemia in humans
AU1678188A (en) Post harvest treatment of produce
UA7955A (uk) Спосіб лікування туберкульозу легенів
MX9405923A (es) Mejoras en proceso para humectar y suavizar la piel.
AU1162788A (en) Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases
NO870398L (no) Fremgangsmaate for fremstilling av terapeutisk aktive organiske platinakomplekser.
EP0692969A4 (en) METHOD FOR TREATING DISEASES BY DELETING T CELLS